Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2011, Vol. 16 ›› Issue (6): 679-687.
Previous Articles Next Articles
HAO Gang, ZHOU Fang, WU Xiao-lan, WANG Guang-ji
Received:
2011-04-13
Revised:
2011-05-12
Published:
2011-07-25
CLC Number:
HAO Gang, ZHOU Fang, WU Xiao-lan, WANG Guang-ji. Progresses of AEG-1 on cancer research[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 679-687.
[1] Su ZZ, Kang DC, Chen Y, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH [J]. Oncogene, 2002, 21(22): 3592-3602. [2] Yoo BK, Emdad L, Lee SG, et al. Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology [J]. Pharmacol Ther, 2011, 130(1): 1-8. [3] Emdada L, Lee SG, Su ZZ, et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis [J]. Proc Natl Acad Sci USA, 2009, 106(50): 21300-21305. [4] Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis [J]. AIDS, 1999, 13(1): 1-22. [5] Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis [J]. Cancer Cell, 2004, 5(4): 365-374. [6] Sutherland HG, Lam YW, Briers S, et al. 3D3/lyric: a novel transmembrane protein of the endo- plasmic reticulum and nuclear envelope, which is also present in the nucleolus [J]. Exp Cell Res, 2004, 294(1): 94-105. [7] Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer [J]. Cancer Cell, 2009, 15(1): 9-20. [8] Yoo BK, Emdad L, Su ZZ, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression [J]. J Clin Invest, 2009, 119(3): 465-477. [9] Lee SG, Su ZZ, Emdad L, et al. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc [J]. Proc Natl Acad Sci USA, 2006, 103(46): 17390-17395. [10] Emdad L, Sarkar D, Su ZZ, et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration[J]. Pharmacol Pharmacol Ther, 2007, 114(2): 155-170. [11] Kang DC, Su ZZ, Sarkar D, et al. Cloning and characterization of HIV-1- inducible astrocyte elevated gene-1 AEG-1 [J]. Gene, 2005, 353(1): 8-15. [12] Thirkettle HJ, Girling J, Warren AY, et al. LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals [J]. Clin Cancer Res, 2009, 15(9):3003-3013. [13] Li J, Zhang N, Song LB, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival [J]. Clin Cancer Res, 2008, 14(11): 3319-3326. [14] Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis [J]. Carcinogenesis, 2009, 30(5): 894-901. [15] Song L, Li W, Zhang H, et al. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer [J]. J Pathol, 2009, 219(3): 317-326. [16] Xia Z, Zhang N, Jin H, et al. Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas [J]. Clin Neurol Neurosurg, 2010, 112(5): 413-419. [17] Lee SG, Jeon HY, Su ZZ, et al. Astrocyte Elevated Gene-1 contributes to the pathogenesis of neuroblastoma [J]. Oncogene, 2009, 28(26): 2476-2484. [18] Meng F, Luo C, Lou G, et al. Clinical significance of astrocyte elevated gene-1 expression in human epithelial ovarian carcinoma[J]. Int J Gynecol Pathol, 2011, 30(2): 145-150. [19] Emdad L, Sarkar D, Lee SG, et al. Astrocyte elevated gene-1: a novel target for human glioma therapy [J]. Mol Cancer Ther, 2010, 9(1): 79-88. [20] Xu JB,Wu H, Zhang CH, et al. (in press). Astrocyte elevated gene-1 overexpression is associated with poor prognosis in gastric cancer [J]. Med Oncol, 2010,28(2):455-462. [21] Song H, Li C, Li R, et al. Prognostic significance of AEG-1 expression in colorectal carcinoma [J]. Int J Colorectal Dis, 2010, 25(10): 1201-1209. [22] Liu L,Wu J, Ying Z, et al. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion [J]. Cancer Res, 2010, 70(9): 3750-3759. [23] Chen W, Ke Z, Shi H, et al. Overexpression of AEG-1 in renal cell carcinoma and its correlation with tumor nuclear grade and progression [J]. Neoplasma, 2010, 57(6): 522-529. [24] Li C, Li R, Song H, et al. Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer [J]. J Surg Oncol, 2011, 103(2):184-192. [25] Thomas SN, Tong Z, Stebe KJ, et al. Identification, characterization and utilization of tumor cell selection ligands in the design of colon cancer diagnostics [J]. Biorheology, 2009, 46(3): 207-225. [26] Li J, Yang L, Song L, et al. Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1 [J]. Oncogene, 2009, 28(36): 3188-3196. [27] Lee SG, Su ZZ, Emdad L, et al. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling [J]. Oncogene, 2008, 27(8): 1114-1121. [28] Emdad L, Sarkar D, Su ZZ, et al. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis [J]. Cancer Res, 2006, 66(3): 1509-1516. [29] Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor [J]. J Mol Med, 2008, 86(6): 623-627. [30] Thirkettle HJ, Mills IG, Whitaker HC, et al. Nuclear lyric/AEG-1 interacts with PLZF and relives PLZF-mediated repression [J]. Oncogene, 2009, 28(41): 3663-3670. [31] Liu J, Yuan Y, Huan J, et al. Inhibition of breast and brain cancer cell growth by BCCIP alpha, an evolutionarily conserved nuclear protein that interacts with BRCA2 [J]. Oncogene, 2001, 20(3): 336-345. [32] Ash SC, Yang DQ, Britt DE. Lyric/AEG-1 overexpression modulates BCCIPα protein levels in prostate tumor cells [J]. Biochem Biophys Res Commun, 2008, 371(2): 333-338. [33] Yoo BK, Santhekadur PK, Gredler R, et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma [J]. Hepatology, 2011,53(5):1538-1548. [34] Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy [J]. Dev Cell, 2004, 6(4) :463-477. [35] Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, et al. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells [J]. Cell Mol Med, 2009, 13(9B):3644-3654. [36] Bhutia SK, Kegelman TP, Das SK, et al. Astrocyte elevated gene-1 induces protective autophagy [J]. Proc Natl Acad Sci USA, 2010, 107(51): 22243-22248. [37] Liu H, Song X, Liu C, et al. Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells [J]. J Exp Clin Cancer Res, 2009, 28(1):19. [38] Sarkar D, Emdad L, Lee SG, et al. Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes [J]. Cancer Res, 2009, 69(22): 8529-8535. [39] Yoo BK,Gredler R, Vozhilla N, et al. Identification of genes conferring resistance to 5-fluorouracil [J]. Proc Natl Acad Sci USA, 2009, 106(31): 12938-12943. [40] Yoo BK, Chen D, Su Z, et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1 [J]. Cancer Res, 2010, 70(8): 3249-3258. |
[1] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[2] | LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130. |
[3] | WANG Fei, HANG Yongfu, WANG Wei. Influence of argumented renal clearance on teicoplannin serum concentrations in critical ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1043-1048. |
[4] | HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535. |
[5] | LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474. |
[6] | YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177. |
[7] | YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990. |
[8] | DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651. |
[9] | LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273. |
[10] | WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286. |
[11] | HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69. |
[12] | LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping. Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399. |
[13] | HAN Guijuan, JIANG Ji, OUYANG Weiwei, LUO Hong, ZHANG Xiaojun, WANG Minghua. Absorption and excretion of CT-707 in healthy male subjects studied by radioisotope tracer method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1407-1412. |
[14] | LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425. |
[15] | ZHANG Miao, LIU Qian, YAO Xueting, LIU Dongyang. Exploration of early food effect study of innovative drugs based on physiologically-based pharmacokinetic absorption model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1426-1429. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||